SELLAS Life Sciences Group Inc buy me8
Start price
30.06.21
/
0%
€13.06
Target price
30.06.22
€16.00
Performance (%)
-39.28%
End price
09.07.21
€7.93
Summary
This prediction ended on 09.07.21 with a price of €7.93. Massive losses of -39.28% were the result for the BUY prediction by me8. This prediction was marked as speculative and is excluded from me8's performance statistics.SELLAS Life Sciences is a clinical-stage biopharmaceutical company focused on the development of novel cancer immunotherapies for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, is a cancer immunotherapy being developed for the treatment of acute myeloid leukemia (AML) and ovarian cancer. SELLAS Life Sciences is listed on the NASDAQ stock exchange under the symbol RXII.
Performance without dividends (%)
| Name | 1w | 1m | 1y |
|---|---|---|---|
| SELLAS Life Sciences Group Inc | -0.459% | -0.459% | -18.033% |
| iShares Core DAX® | -0.258% | 0.299% | 15.648% |
| iShares Nasdaq 100 | 2.964% | 4.660% | 32.001% |
| iShares Nikkei 225® | 1.217% | -2.160% | 6.668% |
| iShares S&P 500 | 1.732% | 2.807% | 25.596% |
According to me8 what are the pros and cons of SELLAS Life Sciences Group Inc for the foreseeable future?
Pros
Could be worthwhile Investment >10% per year
Capable Management
Cons
Little innovation
Comments by me8 for this prediction
In the thread SELLAS Life Sciences Group Inc diskutieren
Buy SELLAS Life Sciences Group Inc
Kursziel gesetzt auf 16,0